Recruiting
Triple negative breast cancer
RecruitingRegistered drugNo placebo
Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment
Registered drugNo placebo
- Disease:Triple negative breast cancer
- Substances:CapecitabineGimeracil+4
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting












